Management of Renal Artery Stenosis: 2010
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Renal artery stenosis (RAS) is a relatively common manifestation of atherosclerosis, although in a small percentage of cases it is due to fibromuscular dysplasia and less frequently may have other etiologies. RAS may be treated by revascularization, using either percutaneous or open surgical techniques. Currently, technical success with percutaneous revascularization utilizing angioplasty and stenting is achieved in 95% or more of cases in which it is attempted. Despite this, at least one third of patients undergoing renal artery stenting do not receive any measurable benefit. Furthermore, randomized trials of stenting for RAS have failed to demonstrate a benefit over medical management alone. Thus, the clinician is faced with a challenge when determining how to manage an individual patient with RAS. In the current era, all patients with RAS should receive “optimal medical therapy.” This approach should use medicines to control blood pressure, and specifically utilize agents proven to reduce cardiovascular morbidity and mortality. Other components of “optimal medical therapy” include the use of anti-platelet drugs such as aspirin and statins to minimize progression of atherosclerosis. In addition to these strategies, consideration should be given to revascularization therapy. When deciding to revascularize RAS, the patient should have an appropriate clinical indication, in addition to a significant anatomic stenosis. Importantly, stents should not be placed due to the “oculostenotic reflex.” Specifically, patients who continue to have uncontrolled blood pressure or worsening renal function despite an aggressive approach with medical therapy may be particularly good candidates for renal artery stenting. Despite the lack of benefit in randomized trials to date, there is likely still a role for renal artery stenting in RAS; however, careful patient selection is essential to maximize the potential benefit.
- Jean WJ, Al-Bittar I, Zwicke DL, et al.: High incidence of renal artery stenosis in patients with coronary artery disease. Catheter Cardiovasc Diagn 1994, 32:8–10. CrossRef
- Olin JW, Melia M, Young JR, et al.: Prevalence of renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990, 88:46N–51N. CrossRef
- Goldblatt H, Lynch J, Hanzal RF, et al.: Studies on experimental hypertension: production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934, 59:347–379. CrossRef
- Mann JFE, Gerstein HC, Dulau-Florea I, et al.: Cardiovascular risk in patients with mild renal insufficiency. Kidney Int 2003, 84:S192–S196. CrossRef
- Holland DC, Lam M: Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000, 15:650–658. CrossRef
- Dzau V: The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 2005, 23(suppl 1):S9–S17. CrossRef
- Montecucco F, Pende A, Mach F: The rennin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediat Inflamm 2009, 2009:752406. Epub 2009
- Harden PN, MacLeod MJ, Rodger RSC, et al.: Effect of renal artery stenting on progression of renovascular renal failure. Lancet 1997, 349:1133–1136. CrossRef
- Dorros G, Jaff M, Mathiak L, et al.: Multicenter Palmaz stent renal artery stenosis revascularization registry report: four-year follow-up of 1, 058 successful patients. Catheter Cardiovasc Interv 2002, 55:182–188. CrossRef
- Plouin PF, Chatellier G, Darne B, et al.: Blood pressure outcomes in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs. Angioplastie (EMMA) Study Group. Hypertension 1998, 31:823–829.
- Webster J, Marshall F, Abdalla M, et al.: Randomised comparison of percutaneous angioplasty vs. continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and New Castle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998, 12:329–335. CrossRef
- van Jaarsveld BC, Krijinen P, Pieterman H, et al.: The effect of balloon angioplasty on hypertension in atherosclerotic renal artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000, 342:1007–1014. CrossRef
- Bax L, Woittiez AJJ, Kouwenberg HJ, et al.: Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function. A randomized trial. Ann Intern Med 2009, 150:840–848.
- The ASTRAL Investigators: Revascularization versus medical therapy for renal artery stenosis. N Engl J Med 2009, 361:1953–1962. CrossRef
- Rousseau D, Helies-Toussaint C, Raederstorff D, et al.: Dietary n-3 polyunsaturated fatty acids affect the development of renovascular hypertension in rats. Mol Cell Biochem 2001, 225:109–119. CrossRef
- Grossman E, Rosenthal T: The effect of sodium restriction in renovascular hypertension. Clin Nephrol 1986, 25:113–115.
- Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486–2497.
- Losito A, Errico R, Santirosi P, et al.: Long term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant 2005, 20:1604–1609. CrossRef
- Hackam DG, Duong-HUA MLD, Mamdani M, et al.: Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J 2008, 156:549–555. CrossRef
- Cooper CJ, Murphy TP, Matsumoto A, et al.: Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J 2006, 152:59–66. CrossRef
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288(23):2981–2997. CrossRef
- Grundy SM, Cleeman JI, Merz CNB, et al.: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004, 110:227–239. CrossRef
- Bates MC, Campbell JC, Stone PA, et al.: Factors affecting long-term survival following renal artery stenting. Cathet Cardiovasc Interv 2007, 69:1037–1043. CrossRef
- Silva VS, Martin LC, Franco RJ, et al.: Pleiotropic effects of statins may improve outcomes in atherosclerotic renovascular disease. Am J Hypertens 2008, 21:1163–1168. CrossRef
- Kanjwal K, Cooper CJ, Virmani R, et al.: Predictors of embolization during protected renal artery angioplasty and stenting: role of antiplatelet therapy. Cathet Cardiovasc Interv 2010, 76:16–23. CrossRef
- Hirsch AT, Haskal ZJ, Hertzer NR, et al.: ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol 2006, 47:1239–1312. CrossRef
- Dorros G, Prince C, Mathiak L: Stenting of a renal artery stenosis achieves better relief of the obstructive lesion than balloon angioplasty alone. Cathet Cardiovasc Diagn 1993, 29:191–198. CrossRef
- Iannone LA, Underwood PL, Nath A, et al.: Effect of primary balloon expandable renal artery stents on long-term patency, renal function, and blood pressure in hypertensive and renal insufficient patients with renal artery stenosis. Cathet Cardiovasc Diagn 1996, 37:243–250. CrossRef
- White CJ: Kiss my astral: one seriously flawed study of renal stenting after another. Cathet Cardiovasc Interv 2010, 75:305–307. CrossRef
- Kalra PA, Chrysochou C, Green D, et al.: The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease. Cathet Cardiovasc Interv 2010, 75:1–10. CrossRef
- Feldman RL, Wargovich TJ, Bittl JA: No-touch technique for reducing aortic wall trauma during renal artery stenting. Cathet Cardiovasc Interv 1999, 46:245–248. CrossRef
- Axelrod DA, Fendrick AM, Carlos RC, et al.: Percutaneous stenting of incidental renal artery stenosis: decision analysis of costs and benefits. J Endovasc Ther 2003, 10:546–556. CrossRef
- van Helvoort-Postulart D, Dirksen CD, Nelemans PJ, et al.: Renal artery stenosis: cost-effectiveness of diagnosis and treatment. Radiology 2007, 244:505–513. CrossRef
- Cambria RP, Brewster DC, L’Italien GJ, et al.: The durability of different reconstructive techniques for atherosclerotic renal artery disease. J Vasc Surg 1994, 20:76–87.
- Modrall JG, Rosero EB, Smith ST, et al.: Operative mortality for renal artery bypass in the United States: results from the National Inpatient Sample. J Vasc Surg 2008, 48:317–322. CrossRef
- Schwarzwalder U, Hauk M, Zeller T: RADAR—a randomized, multi-centre, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with haemodynamically relevant atherosclerotic renal artery stenosis. Trials 2009, 10:60. CrossRef
- Edwards MS, Craven BL, Stafford J, et al.: Distal embolic protection during renal artery angioplasty and stenting. J Vasc Surg 2006, 44:128–135. CrossRef
- Holden A, Hill A, Jaff MR, et al.: Renal artery stent revascularization with embolic protection in patients with ischemic nephropathy. Kidney Int 2006, 70:948–955. CrossRef
- Hagspiel KD, Stone JR, Leung DA: Renal angioplasty and stent placement with distal protection: preliminary experience with the FilterWire Ex. J Vasc Interv Radiol 2005, 16:125–131.
- Holden A, Hill A: Renal angioplasty and stenting with protection of the main renal artery in ischemic nephropathy: early experience. J Vasc Surg 2003, 38:962–968. CrossRef
- Henry M, Klonaris C, Henry I, et al.: Protected renal stenting with the PercuSurge GuardWire device: a pilot study. J Endovasc Ther 2001, 8:227–237. CrossRef
- Li SS, Wong CH, Lam CW, et al.: Renal angioplasty under protection of the PercuSurge GuardWire Plus System. J Invasive Cardiol 2003, 15:148–150.
- Eggebrecht H, Haude M, Baumgart D, et al.: A new temporary occlusion and aspiration system for prevention of distal embolization during percutaneous transluminal renal angioplasty. J Interv Cardiol 2000, 13:339–342. CrossRef
- Cooper CJ, Haller ST, Colyer W, et al.: Embolic protection and platelet inhibition during renal artery stenting. Circulation 2008, 117:2752–2760. CrossRef
- Management of Renal Artery Stenosis: 2010
Current Treatment Options in Cardiovascular Medicine
Volume 13, Issue 2 , pp 103-113
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links